These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 11948109

  • 1. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
    Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.
    Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
    [Abstract] [Full Text] [Related]

  • 2. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ.
    Cancer Res; 2001 Dec 01; 61(23):8513-9. PubMed ID: 11731436
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F.
    Clin Exp Immunol; 2005 Dec 01; 142(3):555-68. PubMed ID: 16297169
    [Abstract] [Full Text] [Related]

  • 4. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.
    Clin Cancer Res; 2003 Nov 01; 9(14):5091-100. PubMed ID: 14613986
    [Abstract] [Full Text] [Related]

  • 5. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J.
    Cancer Res; 2001 Sep 01; 61(17):6451-8. PubMed ID: 11522640
    [Abstract] [Full Text] [Related]

  • 6. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
    Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.
    Am J Respir Crit Care Med; 2010 Jun 15; 181(12):1383-90. PubMed ID: 20167848
    [Abstract] [Full Text] [Related]

  • 7. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A.
    Cancer Res; 2001 Sep 01; 61(17):6445-50. PubMed ID: 11522639
    [Abstract] [Full Text] [Related]

  • 8. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.
    Clin Cancer Res; 2011 Sep 01; 17(17):5725-35. PubMed ID: 21771874
    [Abstract] [Full Text] [Related]

  • 9. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszynska A, Wiesneth M, Schmitt M.
    Int J Oncol; 2006 Apr 15; 28(4):855-61. PubMed ID: 16525634
    [Abstract] [Full Text] [Related]

  • 11. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.
    Cancer J Sci Am; 1998 Apr 15; 4(5):316-23. PubMed ID: 9815296
    [Abstract] [Full Text] [Related]

  • 12. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.
    Int J Oncol; 2003 Mar 15; 22(3):651-6. PubMed ID: 12579320
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
    Shimizu K, Thomas EK, Giedlin M, Mulé JJ.
    Cancer Res; 2001 Mar 15; 61(6):2618-24. PubMed ID: 11289139
    [Abstract] [Full Text] [Related]

  • 14. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon C, Jung CW.
    Clin Immunol; 2007 Dec 15; 125(3):257-67. PubMed ID: 17916447
    [Abstract] [Full Text] [Related]

  • 15. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L.
    J Immunother; 2007 Oct 15; 30(7):762-72. PubMed ID: 17893568
    [Abstract] [Full Text] [Related]

  • 16. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
    Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG.
    Clin Cancer Res; 2005 Nov 01; 11(21):7692-9. PubMed ID: 16278389
    [Abstract] [Full Text] [Related]

  • 17. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
    Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D.
    Clin Cancer Res; 2004 Jul 15; 10(14):4699-708. PubMed ID: 15269142
    [Abstract] [Full Text] [Related]

  • 18. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
    Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS.
    Clin Cancer Res; 2003 Mar 15; 9(3):998-1008. PubMed ID: 12631598
    [Abstract] [Full Text] [Related]

  • 19. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG.
    Cancer Res; 2013 Jan 01; 73(1):19-29. PubMed ID: 23087058
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S.
    Anticancer Res; 2013 Jul 01; 33(7):2971-6. PubMed ID: 23780988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.